Asia-Pacific Biologics Market, By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution) Industry Trends and Forecast to 2030.
Asia-Pacific Biologics Market Analysis and Insights
Biologics are the drugs produced from living organisms or some components of living organisms. These drugs can be derived from different biological sources, including humans, avian cell culture, yeast, bacteria, and insect cell culture among others. These drugs involve therapeutic proteins, monoclonal antibodies, and vaccines. These drugs can be used to treat different types of chronic conditions, including cancers, inflammatory diseases, metabolic diseases, cardiovascular diseases, and infectious diseases.
Asia-Pacific biologics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyzes that the market is growing with a CAGR of 11.5% in the forecast period of 2023 to 2030 and is expected to reach USD 141,276.35 million by 2030.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution).
|
|
Countries Covered
|
China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and rest of Asia-Pacific.
|
|
Market Players Covered
|
AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.
|
Market Definition
Biologics are the drugs produced from living organisms or some components of living organisms that have several advantages compared to other drug types, including small molecules. These are very much target-specific which has enhanced the demand among healthcare professionals. Moreover, the side effects caused are mostly related to exaggerated pharmacological effects, leading to mild health effects. Biologic drugs have also been proven to hold high potential for several therapeutic areas and have revolutionized treatments of several serious illnesses. For instance, Rituximab (chimeric monoclonal antibody) has significantly improved non-Hodkings lymphoma.
The major factor that drives the market growth is the rise in the prevalence of chronic diseases such as diabetes and cancer in developing countries. Furthermore, rise in initiatives by governments and surge in research for new biologics drugs are some of the factors that boost the market growth. However, lack of awareness about healthcare in developing countries is a major factor that restrains the market growth. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for market expansion in the forecast period.
Asia-Pacific Biologics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
- Rising prevalence of chronic diseases such as diabetes and cancers
Chronic diseases are one of the biggest healthcare concerns in the world, claiming an estimated 40 million lives every year, 8.5 million of whom reside in Asia. In Asia-Pacific, cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions are among the most common chronic diseases. This is primarily driven by aging populations and poor lifestyle choices such as the lack of physical activity and tobacco & alcohol consumption.
- Changes in lifestyle
Lifestyle diseases share risk factors similar to prolonged exposure to three modifiable lifestyle behaviors, smoking, unhealthy diet, and physical inactivity, and result in the development of chronic diseases, specifically heart disease, stroke, diabetes, obesity, metabolic syndrome, Chronic Obstructive Pulmonary Disease (COPD), and some types of cancer.
- Recent advancements in biologics
Delivery by injection is the most convenient method for biologics delivery. It is not always ideal. This is primarily because of the pharmacokinetics of biologics, which means they are rapidly cleared from systemic circulation.
Co-formulation of therapeutics is an emerging strategy that aims to capitalize on advances in therapeutic effects observed through the co-administration of biologics.
RESTRAINTS
- Complex manufacturing process of biologics
Biologics drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as Critical Quality Attributes (CQAs), can vary based on post-translational modifications that occur in the cellular environment or during the manufacturing process. The complexity of the manufacturing process leads to several defaults. Thus, the complex manufacturing process of biologics is acting as a major restraining factor for market growth.
- Adverse side-effects of biologics
Like standard pharmaceuticals, biological treatments can cause adverse drug reactions. They can cause allergic reactions similar to the ways these drugs can. But they can also cause problems due to the way biologics interact with the immune system. They can also sometimes cause specific issues with various organ systems in the body.
Some of the side effects associated with biologics are:
- Injection site reactions
- Infusion reactions
Usually, these reactions are mild. However, sometimes they may be more severe such as hypersensitivity reactions, and require medical intervention.
Thus, adverse side effects of biologics treatment act as a restraint for market growth.
OPPORTUNITIES
- Rising healthcare expenditure
Across the globe, R&D activities are escalating owing to public health expenditure with economic performance. At the same time, the healthcare industry ranks second among all industries regarding R&D. Rising healthcare expenditure can result in better provision of R&D opportunities. That results in the anticipated upsurging demand for various cancer diagnostics.
- Strategic initiatives by market players
An increase in the burden of various types of diseases such as cancers, diabetes, and cardiovascular diseases across Asia-Pacific, coupled with the rise in the geriatric population, has created more demand for biologics. The main aim is to improve health management in biologics for quality care with convenient application. Hence, major market players are focusing on fulfilling the demand for biologics and spending a noticeable amount on better products.
Thus, these strategic product launches, acquisitions, and mergers by major companies in the biologics market have opened up opportunities for companies in Asia. This strategy is allowing the companies to strengthen their footprints in the market.
- Surge in healthcare expenditure
Healthcare expenditure has increased across Asia-Pacific region, as the disposable income of people across Asia is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare organizations to improve their treatment facilities for the usage of biologics.
- Growing number of biopharmaceutical contract manufacturing companies in Asia
The biopharmaceutical contract manufacturing market is growing essentially due to the increasing demand for biologics and increasing outsourcing by pharmaceutical companies in Asia-Pacific. Increasing competition in the industry is likely to damage the market growth in the coming years. Additionally, robust advancements in R&D activities, emerging markets, and consolidation in the pharmaceutical CMO industry are likely to increase the growth of biopharmaceutical contract manufacturing companies during the forecast period.
The growing number of biopharmaceutical contract manufacturing companies leads to the development of new products via rigorous research to treat various diseases. Thus, this acts as an opportunity for market growth.
CHALLENGE
- Stringent regulatory policies
Regulation of drugs plays a significant role in healthcare. Achieving the requisite approval for the legal selling of medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or taken into account, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins among others are of significant importance for treating various diseases. But their approval and marketing in multiple regions across Asia require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.
Thus, the above-mentioned stringent regulations and policies for approving the complicated nature of biologics act as a challenge to market growth.
Post-COVID-19 Impact on Asia-Pacific Biologics Market
The COVID-19 pandemic had somewhat negative impact on the biologics market. Due to the pandemic, new norms and regulations were imposed, such as social distancing and lockdown to prevent the spread of virus. As a result, people all over the world were forced to stay at home. This stay-at-home led to a decrease in the consumption of biologics, which further led to a decrease in the demand for biologics.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the quality of biologics existing in the market.
Recent Developments
Many product launches and agreements are also initiated by companies worldwide which are accelerating the market growth.
- In November 2021, Biocon launched Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in collaboration with Viatris Inc. The new product launch helped patients control high blood sugar in adults and pediatric patients suffering from diabetes 1 and diabetes 2.
- In December 2019, Bharat Biotech launched ROTAVAC 5D-lowest dose volume rotavirus vaccine across the world. The product launch was developed in partnership with the Department of Biotechnology, Government of India.
Asia-Pacific Biologics Market Scope
Asia-Pacific biologics market is segmented into seven notable segments based on class, type, route of administration, application, source material, end user, and distribution channel.
By Class
- Tumor Necrosis Factor-Α (TNF) Inhibitors
- B-Cell Inhibitors
- Interleukin Inhibitors
- Selective Co-Stimulation Modulators (Abatacept)
- Others
Based on class, the market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others.
By Type
- Monoclonal Antibodies (mABs)
- Therapeutic Proteins
- Vaccines
- Cellular Based Biologics
- Gene Based Biologics
- Other
Based on type, the market is segmented into monoclonal antibodies (mABs), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and other.
By Route of Administration
- Injection
- Infusion
Based on route of administration, the market is segmented into injection, and infusion.
By Application
- Oncology
- Autoimmune Diseases
- Diabetes
- Infectious Diseases
- Cardiovascular Diseases
- Ophthalmic Diseases
- Dermatological Diseases
- Others
Based on application, the market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others.
By Source Material
- Humans
- Avian Cell Culture
- Yeast
- Bacteria
- Insects Cell Culture
- Transgenics
- Others
Based on source material, the market is segmented into humans, avian cell culture, yeast, bacteria, insect cell culture, transgenics, and others.
By End User
- Hospital
- Specialty Clinics
- Academics and Research Institutes
- Others
Based on end user, the market is segmented into hospitals, specialty clinics, academics and research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Third Party Distribution
Based on distribution channel, the market is segmented into direct tender, retail sales, and third party distribution.
Asia-Pacific Biologics Market Regional Analysis/Insights
The Asia-Pacific biologics market is analyzed and market size information is provided based on country, class, type, route of administration, application, source material, end user, and distribution channel.
In 2022, Asia-Pacific was growing due to the rising prevalence of chronic diseases such as diabetes and cancer. China is expected to dominate the market due to recent advancements in biologics.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Biologics Market Share Analysis
Asia-Pacific biologics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus related to the market.
Some of the major players operating in this market are AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.
SKU-
